Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis.
Mauricio Sarmiento MaldonadoPablo Ramírez VillanuevaPablo Bertín Cortes-MonroyVeronica Jara AriasKatherine Soto DonosoPablo Uribe GonzalezMauricio Ocqueteau TachiniJose Antonio Perez-SimónPublished in: Experimental hematology & oncology (2017)
In our series, Ruxolitinib was very active as a rescue therapy for patients with acute or chronic GVHD refractory to standard treatment.